{"id":342409,"date":"2026-11-06T22:22:35","date_gmt":"2026-11-06T16:52:35","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/gland-pharma-q2-results-fy27-pat-291-crore\/"},"modified":"2026-11-06T22:22:35","modified_gmt":"2026-11-06T16:52:35","slug":"gland-pharma-q2-results-fy27-pat-291-crore","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/gland-pharma-q2-results-fy27-pat-291-crore\/","title":{"rendered":"Gland Pharma Q2 Results FY27: PAT Jumps 58.3% to Rs 290.76 Cr, Revenue Rs 1,833.59 Cr"},"content":{"rendered":"
\n

Quick Answer<\/strong><\/p>\n

Gland Pharma Q2 Results FY27 were declared on 6 November 2026 for the July to September 2026 quarter. Consolidated revenue stood at Rs 1,833.59 Cr, up 23.32% YoY from Rs 1,486.88 Cr, while net profit came in at Rs 290.76 Cr, up 58.3% YoY from Rs 183.68 Cr. These quarterly results, reported as consolidated results, show YoY growth on both lines.<\/p>\n<\/div>\n

Gland Pharma Ltd (GLAND) Q2 Results FY27 announced on 6 November 2026, covering the company’s financial performance for the July to September 2026 quarter. The consolidated results show revenue of Rs 1,833.59 Cr and PAT of Rs 290.76 Cr, and Gland Pharma Q2 Results FY27 set the results date that anchors every figure in this article.<\/p>\n

This results analysis of Gland Pharma Q2 Results tracks the reported numbers on NSE and BSE through financial highlights, business drivers, outlook and risks, and it begins with the table of reported figures below.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n